HUTCHMED Announces Licensing Agreement with GSK for KRAS-EGFR-Antibody Conjugate Cancer Therapy

Impact · against what's priced in

HUTCHMED receives a significant valuation boost from a high-profile partnership with GSK, securing $110 million upfront and up to $1.295 billion in potential milestones. For GSK, the deal provides a first-in-class oncology asset, though the impact is smaller given its scale and the distant clinical timeline.

HCM+0.70

No priced-in read yet